Case characteristics, hyperacute treatment, and outcome information from the clinical research center for stroke-fifth division registry in South Korea

Journal of Stroke

Volumn 17, Issue 1, 2015, Pages 38-53

  Kim, Beom Joon ^a   Park, Jong Moo ^b   Kang, Kyusik ^c   Lee, Soo Joo ^c   Ko, Youngchai ^c   Kim, Jae Guk ^c   Cha, Jae Kwan ^d   Kim, Dae Hyun ^d   Nah, Hyun Wook ^d   Han, Moon Ku ^a   Park, Tai Hwan ^e   Park, Sang Soon ^e   Lee, Kyung Bok ^f   Lee, Jun ^g   Hong, Keun Sik ^h   Cho, Yong Jin ^h   Lee, Byung Chul ⁱ   Yu, Kyung Ho ⁱ   Oh, Mi Sun ⁱ   Kim, Dong Eog ^j   Ryu, Wi Sun ^j   Cho, Ki Hyun ^k   Kim, Joon Tae ^k   Choi, Jay Chol ^l   Kim, Wook Joo ^m   Shin, Dong Ick ⁿ   Yeo, Min Ju ⁿ   Sohn, Sung Il ^o   Hong, Jeong Ho ^o   Lee, Juneyoung ^p   Lee, Ji Sung ^q   Yoon, Byung Woo ^r   Bae, Hee Joon ^a   more..

^a Seoul National University Bundang Hospital   (South Korea)

^b Eulji General Hospital   (South Korea)

^c Eulji University   (South Korea)

^d Dong A University College of Medicine   (South Korea)

^e Seoul Medical Center   (South Korea)

^f Soonchunhyang University College of Medicine   (South Korea)

^g Yeungnam University Hospital   (South Korea)

^h Inje University   (South Korea)

ⁱ Hallym University   (South Korea)

^j Dongguk University Ilsan Hospital   (South Korea)

^k Chonnam National University Medical School   (South Korea)

^l Jeju National University Hospital   (South Korea)

^m University of Ulsan College of Medicine   (South Korea)

ⁿ Chungbuk National University Hospital   (South Korea)

^o Dongsan Medical Center   (South Korea)

^p Korea University   (South Korea)

^q Asan Medical Center   (South Korea)

^r Seoul National University Hospital   (South Korea)

more..

Author keywords

Case profile; Hyperacute treatment; Outcome; Recurrent event; South Korea; Stroke registry; Thrombolysis

Indexed keywords

ALTEPLASE;

AGE; CEREBROVASCULAR ACCIDENT; DISEASE REGISTRY; ENDOVASCULAR SURGERY; HEALTH CARE UTILIZATION; HUMAN; LENGTH OF STAY; MORTALITY; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PREVALENCE; RANKIN SCALE; RECANALIZATION; RECURRENT DISEASE; REVIEW; RISK FACTOR; SOUTH KOREA; TIME TO TREATMENT; TRANSIENT ISCHEMIC ATTACK;

EID: 84937036283     PISSN: 22876391     EISSN: 22876405     Source Type: Journal    
DOI: 10.5853/jos.2015.17.1.38     Document Type: Review

References (45)

1. Bufalino VJ, Masoudi FA, Stranne SK, Horton K, Albert NM, Beam C, et al. The American Heart Association’s recommenda­tions for expanding the applications of existing and future clini­cal registries: a policy statement from the American Heart As­sociation. Circulation 2011;123:2167-2179.
2. Gliklich RE, Dreyer NA. Registries for Evaluating Patient Out­comes: A User’s Guide. 2nd ed. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010.
3. Maasland L, van Oostenbrugge RJ, Franke CF, Scholte OP, Re­imer WJM, Koudstaal PJ, et al. Patients enrolled in large ran­domized clinical trials of antiplatelet treatment for prevention after transient ischemic attack or ischemic stroke are not repre­sentative of patients in clinical practice: the Netherlands Stroke Survey. Stroke 2009;40:2662-2668.
4. Hammill BG, Hernandez AF, Peterson ED, Fonarow GC, Schul­man KA, Curtis LH. Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J 2009; 157:995-1000.
5. Lee BC, Roh JK. International Experience in Stroke Registries. Am J Prev Med 2006;31:S243-S245.
6. Kim BJ, Han M-K, Park TH, Park S-S, Lee KB, Lee B-C, et al. Current status of acute stroke management in Korea: a report on a multicenter, comprehensive acute stroke registry. Int J Stroke 2014;9:514-518.
7. Maeda K, Toyoda K, Minematsu K, Kobayashi S. Effects of Sex Difference on Clinical Features of Acute Ischemic Stroke in Ja­pan. J Stroke Cerebrovasc Dis 2013;22:1070-1075.
8. Hsieh FI, Chiou HY. Stroke: morbidity, risk factors, and care in taiwan. J Stroke 2014;16:59-64.
9. Tong D, Reeves MJ, Hernandez AF, Zhao X, Olson DM, Fonar­ow GC, Schwamm LH, Smith EE. Times From Symptom On­set to Hospital Arrival in the Get With The Guidelines-Stroke Program 2002 to 2009: Temporal Trends and Implications. Stroke 2012;43:1912-1917.
10. Hong KS, Bang OY, Kang DW, Yu KH, Bae HJ, Lee JS, et al. Stroke Statistics in Korea: Part I. Epidemiology and Risk Fac­tors: A Report from the Korean Stroke Society and Clinical Re­search Center for Stroke. J Stroke 2013;15:2-20.
11. Béjot Y, Troisgros O, Gremeaux V, Lucas B, Jacquin A, Khoumri C, et al. Poststroke disposition and associated factors in a popu­lation-based study: the Dijon Stroke Registry. Stroke 2012;43: 2071-2077.
12. Qureshi AI, Chaudhry SA, Sapkota BL, Rodriguez GJ, Suri MFK. Discharge destination as a surrogate for Modified Rankin Scale defined outcomes at 3- and 12-months poststroke among stroke survivors. Arch Phys Med Rehabil 2012;93:1408-1413.
13. Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S, et al. Temporal Trends in Patient Characteristics and Treat­ment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines-Stroke Hospitals. Circ Cardiovasc Qual Outcome 2013;6:543-549.
14. Cheng S, Claggett B, Correia AW, Shah AM, Gupta D. Tempo­ral Trends in the Population Attributable Risk for Cardiovascu­lar Disease: The Atherosclerosis Risk in Communities Study. Circulation 2014;130:820-828.
15. Kaur P, Kwatra G, Kaur R, Pandian JD. Cost of stroke in low and middle income countries: a systematic review. Int J Stroke 2014;9:678-682.
16. Deng Y, Jiao Y, Hu R, Wang Y, Wang Y, Wang Y, et al. Reduc­tion of length of stay and costs through the implementation of clinical pathways for stroke management in China. Stroke 2014; 45:e81-3.
17. Fonarow GC, Reeves MJ, Smith EE, Saver JL, Zhao X, Olson DW, et al. Characteristics, Performance Measures, and In-Hospi­tal Outcomes of the First One Million Stroke and Transient Isch­emic Attack Admissions in Get With The Guidelines-Stroke. Circ Cardiovasc Qual Outcome 2010;3:291-302.
18. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute isch­aemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014;384:1929-1935.
19. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, et al. The benefits and harms of intravenous throm­bolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke tri­al [IST-3]): a randomised controlled trial. Lancet 2012;379: 2352-2363.
20. Chao AC, Hsu HY, Chung CP, Liu CH, Chen CH, Teng MMH, P et al. Outcomes of Thrombolytic Therapy for Acute Ischemic Stroke in Chinese Patients: The Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study. Stroke 2010;41: 885-890.
21. Hassan AE, Chaudhry SA, Grigoryan M, Tekle WG, Qureshi AI. National trends in utilization and outcomes of endovascu­lar treatment of acute ischemic stroke patients in the mechani­cal thrombectomy era. Stroke 2012;43:3012-3017.
22. Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, et al. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 2012;380:1241-1249.
23. Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, et al. Trevo versus Merci retrievers for thrombec­tomy revascularisation of large vessel occlusions in acute isch­aemic stroke (TREVO 2): a randomised trial. Lancet 2012; 380:1231-1240.
24. Mokin M, Dumont TM, Veznedaroglu E, Binning MJ, Liebman KM, Fessler RD, et al. Solitaire Flow Restoration Thrombecto­my for Acute Ischemic Stroke: Retrospective Multicenter Anal­ysis of Early Postmarket Experience After FDA Approval. Neu­rosurgery 2013;73:19-26.
25. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al. Endovascular Therapy after Intravenous t-PA versus t-PA Alone for Stroke. N Engl J Med 2013;368:893-903.
26. Ciccone A, Valvassori L, Nichelatti M, Sgoifo A, Ponzio M, Ster­zi R, et al. Endovascular Treatment for Acute Ischemic Stroke. N Engl J Med 2013;368:904-913.
27. Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, et al. A Trial of Imaging Selection and Endovascular Treatment for Ischemic Stroke. N Engl J Med 2013;368:914-923.
28. Wang Z, Li J, Wang C, Yao X, Zhao X, Wang Y, et al. Gender Differences in 1-Year Clinical Characteristics and Outcomes af­ter Stroke: Results from the China National Stroke Registry. PLoS ONE 2013;8:e56459.
29. Petty GW, Brown RD, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO. Ischemic Stroke Subtypes : A Population-Based Study of Functional Outcome, Survival, and Recurrence. Stroke 2000;31:1062-1068.
30. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence stud­ies. Neurology 2004;62:569-573.
31. Jackson C. Comparing risks of death and recurrent vascular events between lacunar and non-lacunar infarction. Brain 2005; 128:2507-2517.
32. Hong KS, Kang DW, Koo JS, Yu KH, Han MK, Cho YJ, et al. Impact of neurological and medical complications on 3-month outcomes in acute ischaemic stroke. Eur J Neurol 2008;15: 1324-1331.
33. Weimar C, Mieck T, Buchthal J, Ehrenfeld CE, Schmid E, Die­ner H.C., et al. Neurologic worsening during the acute phase of ischemic stroke. Arch Neurol 2005;62:393-397.
34. Petty GW, Brown RD, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO. Survival and recurrence after first cerebral infarc­tion A population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 1998;50:208-216.
35. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, et al. Long-Term Risk of First Recurrent Stroke in the Perth Community Stroke Study. Stroke 1998;29:2491-2500.
36. Hillen T. Cause of Stroke Recurrence Is Multifactorial: Patterns, Risk Factors, and Outcomes of Stroke Recurrence in the South London Stroke Register. Stroke 2003;34:1457-1463.
37. WHO MONICA Proejct Principal Investigators. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major interna­tional collaboration. WHO MONICA Project Principal Inves­tigators. J Clin Epidemiol 1988;41:105-114.
38. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for preven­tion of death, myocardial infarction, and stroke in high risk pa­tients. BMJ 2002;324:71-86.
39. Dhamoon MS, Sciacca RR, Rundek T, Sacco RL, Elkind MSV. Recurrent stroke and cardiac risks after first ischemic stroke: The Northern Manhattan Study. Neurology 2006;66:641-646.
40. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau C-S, et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observation­al investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 2006;151:786.e1-786.e10.
41. Hsieh FI, Lien LM, Chen ST, Bai CH, Sun MC, Tseng HP, et al. Get With The Guidelines-Stroke Performance Indicators: Surveil­lance of Stroke Care in the Taiwan Stroke Registry: Get With The Guidelines-Stroke in Taiwan. Circulation 2010;122:1116-1123.
42. Kimura K, Kazui S, Minematsu K, Yamaguchi T. Analysis of 16,922 Patients with Acute Ischemic Stroke and Transient Ischemic Attack in Japan. Cerebrovasc Dis 2004;18:47-56.
43. Fonarow GC, Reeves MJ, Smith EE, Saver JL, Zhao X, Olson DW, et al. Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in get with the guidelines-stroke. Circ Cardiovasc Quality Outcome 2010;3:291-302.
44. Wang Y, Cui L, Ji X, Dong Q, Zeng J, Wang Y, et al. The China National Stroke Registry for patients with acute cerebrovascular events: design, rationale, and baseline patient characteristics. Int J Stroke 2011;6:355-361.
45. Wang Y, Liao X, Zhao X, Wang DZ, Wang C, Nguyen-Huynh MN, et al. Using Recombinant Tissue Plasminogen Activator to Treat Acute Ischemic Stroke in China: Analysis of the Results From the Chinese National Stroke Registry (CNSR). Stroke. 2011;42:1658-1664.